Pathology of the breast Flashcards

1
Q

Anatomic locations for breast lesions

A
  • Paget’s disease: nipple and areoli
  • Nipple adenoma: lobar ducts (btwn lactiferous sinus and nipple)
  • Papillomas: lactiferous (major) ducts
  • Traumatic fat necrosis: periphery of breast (fat pad)
  • Hyperplasia, CA, cysts, fibroadenomas: usually in periphery (glandular tissue) and TDLU (lobule and/or terminal duct)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fibrocystic change 1

A
  • Non-neoplastic, benign lesion of the breast, very common
  • Affects multiple areas of breast bilaterally
  • Presents as lumpy-bumpy nodular masses and changes w/ menstrual cycle
  • Micro of non-proliferative: fibrosis of storma, variably sized terminal duct cysts, apocrine metaplasia, increased lymphocytic infiltrate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Fibrocystic change 2

A
  • In proliferative change there’s additional findings: either ductal hyperplasia w/o atypia (lumen epithelial layer is still simple epithelium) or with atypia (lumen epithelia becomes stratified)
  • W/o atypia has 2 fold increase risk of CA, but w/ atypic there is 4-5 fold increased risk for CA
  • There may also be sclerosing adenosis of the TDLU/small ducts, characterized by prominent intracellular fibrosis (may be misdiagnosed by CA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mastitis 1

A
  • Acute: bacterial infection of the breast, most frequently in postpartum lactation
  • Secondary to nipple cracking/fissuring, most commonly from staph/strep
  • Staph infections may progress to abscess formation
  • Signs: acute inflammation grossly and PMNs under micro
  • Granulomatous mastitis (rare): associated w/ mycobacterial, fungal, or systemic granulomatous diseases (sarcoid), also can be from leakage of silicone implants
  • Histo: giant cells, macs, granulomas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mastitis 2

A
  • Fat necrosis: usually secondary to Hx of trauma, surgery
  • Small palpable mass +/- pain
  • Histo: necrotic fat cells surrounded by lipid-laden and hemosiderin-laden macs and PMNs
  • Followed by lymphocytic infiltration and fibrosis to wall off, then replaced by scar tissue (calcification common)
  • Results in irregular, fixed, hard palpable mass that can resemble breast CA (must distinguish)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fibro-adenoma

A
  • Neoplastic, benign proliferation of stromal and glandular tissue
  • Tend to be in young women and multiple/bilateral
  • On palpation its a discrete, nodular/lobulated, rubbery lesion (highly variable size) that is freely movable and well circumscribed
  • Histo: stroma demonstrates a myxoid (more common) or fibrous/hyaline appearance, ductal epithelium often have nl appearance w/ hyperplastic cell layers
  • Ductal epithelium may be attenuated (irregular slit-like structures) due to compression from surrounding stroma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Papilloma

A
  • Benign papillary neoplasm arising in duct
  • Central fibrovascular stalk extends from wall and branches into multiple projections
  • Most tumors are solitary and occur in lactiferous ducts
  • Clinical: bloody or serous nipple discharge
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk factors for developing breast CA

A
  • 2 most important ones: female and old age (>50)
  • Others: early menarche, late menopause, nulliparous, lack of breast feeding, lack of physical exercise, family Hx (BRCA1/2, li-fraumeni)
  • 99% of cancers are carcinomas (origins in ducts or lobules), 1% are sarcomas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pathways for developing breast CA

A
  • Hormonal stimulation (E+P) causes breast cell proliferation-> DNA replication errors/mutations
  • 3 types of breast CAs: ER+ (HER2-), HER2+ (ER+/-), and ER- (HER2-)
  • HER2+ is overexertion of HER2
  • These different types are important for Rx of the CA
  • Most CAs are found by abnormal mammograms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ductal CA in situ (DCIS)

A
  • Malignant ductal epithelial cells limited to ducts and lobules (intact duct/lobule basement membrane)
  • Several different patters, most cases are mixed
  • Comedo: central necrosis often w/ micro calcifications
  • Solid: cells completely fill duct
  • Cribiform: cells are separated and sharply defined, regularly distributed spaces (look like mini-ducts w/in duct filled w/ cells)
  • Micropapillary: papillary projections in the lumen of the duct (no fibrovascular core)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Paget disease of the breast

A
  • Uncommon variant of DCIS or ductal CA in which there is intraepidermal spread of malignant cells from lactiferous ducts to nipple surface
  • Tumor cells (paget cells) that migrate out the duct to the surface disrupt the normal squamous epithelium, resulting in seepage of fluid onto nipple and areola
  • If an erythematous nipple surface w/ weeping, scaly crust is present (mimic eczema) in a pt w/ underlying palpable mass (1/2 of pagets pts have masses) then think paget’s disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Lobular CA in situ (LCIS)

A
  • Almost always incidental finding on Bx, seldom associated w/ stream rxn or calcifications (usually no mammography of PE findings)
  • Small, round, uniform, and loosely cohesive cells pack and distend acini (do not create palpable mass)
  • Lesions are often multifocal, bilateral and increase risk of invasive CA in either breast
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Invasive ductal CA 1

A
  • 80% of invasive breast CA (invasive breast CA 80% of total breast CA, other 20% are CA in situ)
  • Lesions do not have consistent histo findings, clinically more aggressive
  • Can be well-differentiated: resembles well-formed glands
  • Can be poorly differentiated: cords or solid sheets of epithelial cells
  • Often are accompanied by various grades of DCIS
  • Usually does present as a hard, fixed mass on palpation (scirrhous breast CA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Invasive ductal CA 2

A
  • Advanced disease may be associated w/ swollen, dimpled, and thickened overlying skin from stromal infiltration and lymphatic obstruction (peau d’orange)
  • Picked up as mammography densities +/- calcifications
  • Well-differentiated tumors typically express hormone (E/P) receptors and are HER2-
  • Reverse is true for poorly differentiated CAs (but there can be both)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Invasive lobular CA

A
  • 10% of invasive breast CA
  • Cells are morphologically similar to those in LCIS w/ diffuse invasion patter
  • Classic findings: short, single-file chain or strands of cells infiltrating btwn collagen fibers
  • Mucin-producing variant may lead to signet ring appearance
  • Cells are indistinguishable from LCIS and often accompanied by adjacent LCIS
  • 75% present similarly to ductal CA (palpable mass and mammography densities), but 25% have diffuse (occult) disease
  • Vast majority are ER/PR+ and HER2-
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prognostic and predictive markers

A
  • Prognostic markers: predicts outcome independent of Rx
  • Includes anatomic path (invasive/in situ, mets/lymph node status, tumor size, inflammation), ER+/PR+, HER2 expression, microchip array analysis (mammaprint)
  • Minor prognostic factors: histo subtypes and grading, proliferative rates, DNA ploidy, lymphovascular invasion
  • Predictive markers: predicts responsiveness to Rx
  • Includes ER+/PR+, HER2 expression
17
Q

Rx responsiveness markers 1

A
  • ER+PR+ tumors respond very well to anti-E drugs (tamoxifen, aromatase inh)
  • 75% of breast CA will have at least one (ER and/or PR) receptor positive, which confers a favorable response to anti-E Rx (only 25% are ER-/PR-)
  • HER2 (oncogene) is on chrom 17q and is overexpressed in some CAs (20-30%)
  • 17q over expression is detected by FISH
18
Q

Rx responsiveness markers 2

A
  • HER2 is a type of EGF receptor, when HER2 is activated it leads to cell signaling (via tyrosine kinases) that leads to proliferation
  • When HER2 is over expressed and there are higher than nl levels of it on the cell surface it activates itself (w/o EGF binding) and sends the cell signals leading to constitutive proliferation
  • HER2+ tumors respond to the drug Trastuzumab (herceptin), which is an anti-HER2 Ab, and tyrosine kinase inhibitors
19
Q

Familial breast CA

A
  • Primarily due to mutations in either BRCA1 (chrom 17) or BRCA2 (chrom 32)
  • Much more rare is Li-Fraumeni, due to mutations in p53
  • Think familial if breast CA in <30 yo
  • When BRCAs are mutated other forms of DNA repair take over (NHEJ or single strand annealing, SSA- less precise) and lead to more mutations
20
Q

BRCA1

A
  • Hereditary breast-ovarian CA (50% of hereditary breast CAs)
  • 80% lifetime risk of breast and 30% lifetime risk of ovarian CA
  • Usually breast CA in 40s/50s, bilateral breast CA, can be breast + ovarian CA
  • Functions of BRCA1 (tumor suppressor): transcriptional regulation, DNA (double strand break) repair, cell cycle progression, apoptosis induction
  • Mutations can be distributed throughout the coding region
  • About 85% result in introduction of premature stop codons (nonsense)
  • High prevalence among jews
21
Q

BRCA2

A
  • About 1/3rd of hereditary breast CAs, females have increased risk of breast CA, males have increased risk of breast and pancreatic CA
  • Usually breast CA around 50, bilateral breast CA
  • Functions of BRCA2 (tumor suppressor): transcriptional regulation, DNA (double strand break) repair
  • Mutations can be distributed throughout the coding region
  • Most mutations are frame-shift mutations leading to nonsense codons
  • Also high prevalence among jews
  • BRCA2 mutant cells are exquisitely sensitive to PARP inhibitor, can be used in BRCA2 Rx